Filter byLast updatedSelectAfterBeforeFrom - ToDateEnd DateCategoryHumanCorporateVeterinaryHerbalTopicMedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceAdvanced therapiesCompliance and inspectionsData on medicinesClinical trialsInnovationResearch and developmentBiosimilarsSMEAntimicrobial resistanceMedicine shortagesBrexitQuality of medicinesGeneric and hybrid medicinesGovernanceEarly accessProduct informationFeesScientific adviceCorporateMedicines for use outside the EUMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionProcurementDiseases areaViral diseasesCancerImmune-system diseasesNeurodegenerative diseasesCardiovascular diseasesDiabetesHIV and AIDSTreatment of human immunodeficiency virus type 1 (HIV-1) infectionResponsible bodyCHMPCVMPPRACManagement BoardCOMPPDCOCMDhHMPCCATPatient safetyYesFiltersResults (3620) Sort byLast update date (new to old)Last update date (old to new)A-ZZ-ACall for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee3 November 2023NewsHumanCorporateMedicinesEMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.531 October 2023NewsHumanCOVID-19VaccinesEMA business hours over All Saints' Day and All Souls' Day, 1 and 2 November30 October 2023NewsCorporateMeeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 202327 October 2023NewsHumanPharmacovigilanceReferralsEMA takes further steps to address critical shortages of medicines in the EU24 October 2023NewsHumanMedicine shortagesEMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens18 October 2023NewsHumanMedicinesNew treatment option for heavily pre-treated multiple myeloma patients13 October 2023NewsHumanMedicinesMeeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 202313 October 2023NewsHumanMedicinesReferralsMeeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 202312 October 2023NewsVeterinaryMedicinesMonitoring of products originating from Japan for the possibility of radioactivity11 October 2023NewsPrevious456789101112Next
Call for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee3 November 2023NewsHumanCorporateMedicines
EMA recommends approval of adapted Nuvaxovid COVID-19 vaccine targeting Omicron XBB.1.531 October 2023NewsHumanCOVID-19Vaccines
EMA business hours over All Saints' Day and All Souls' Day, 1 and 2 November30 October 2023NewsCorporate
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 202327 October 2023NewsHumanPharmacovigilanceReferrals
EMA takes further steps to address critical shortages of medicines in the EU24 October 2023NewsHumanMedicine shortages
EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens18 October 2023NewsHumanMedicines
New treatment option for heavily pre-treated multiple myeloma patients13 October 2023NewsHumanMedicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 202313 October 2023NewsHumanMedicinesReferrals
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 202312 October 2023NewsVeterinaryMedicines
Monitoring of products originating from Japan for the possibility of radioactivity11 October 2023News